Macrolide-inducible resistance to clindamycin and the D-test

Pediatric Infectious Disease Journal

Volumn 28, Issue 12, 2009, Pages 1115-1118

  Woods, Charles R ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Clindamycin; D test; Macrolide resistance

Indexed keywords

CLINDAMYCIN; ERYTHROMYCIN; LINCOSAMIDE DERIVATIVE; MACROLIDE; MIKAMYCIN B;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL GENE; BACTERIUM IDENTIFICATION; CROSS RESISTANCE; D TEST; DISK DIFFUSION; DRUG EFFECT; ERM GENE; HUMAN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS INFECTION;

EID: 74049089970     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181c35cc5     Document Type: Article

References (23)

1. Feigin RD, Pickering LK, Anderson D, et al. Clindamycin treatment of osteomyelitis and septic arthritis in children. Pediatrics. 1975;55:213-223.
2. Martinez-Aguilar G, Hammerman W, Mason E Jr, et al. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococ-cus aureus in children. Pediatr Infect Dis J. 2003;22:593-598.
3. Frank AL, Marcinak J, Mangat P, et al. Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pe-diatr Infect Dis J. 2002;21:530-534.
4. Chambers HF. Protein synthesis inhibitors. In: Brunton LL, ed. The Pharmacologic Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill; 2006:1188-1190.
5. Ruebner R, Keren R, Coffin S, et al. Complications of central venous catheters used for the treatment of acute hematogenous osteomyelitis. Pediatrics. 2006;117:1210-1215.
6. Jacobs MR, Good CE, Beall B, et al. Changes in serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae strains in Cleveland: a quarter century of experience. J Clin Microbiol. 2008;46:982-990.
7. Richter SS, Heilmann K, Beekman S, et al. Macrolide-resistant Streptococcus pyogenes in the United States, 2002-2003. Clin Infect Dis. 2005;41:599-608.
8. Barber M, Waterworth P. Antibacterial activity of lincomycin and pristinamycin: a comparison with erythromycin. Br Med J. 1964;2:603-606.
9. McGehee RF, Barrett F, Finland M. Resistance of Staphylococcus aureus to lincomycin, clinimy-cin, and erythromycin. Antimicrob Agents Che-mother. 1968;8:392-397.
10. Sande M, Johnson M. Antimicrobial therapy of experimental endocarditis caused by Staphylo-coccus aureus. J Infect Dis. 1975;131:367-375.
11. Watanakunakorn C. Clindamycin therapy of Staphylococcus aureus endocarditis. Am J Med. 1976;60:419-425.
12. Lewis JS, Jorgensen J. Inducible clindamycin resistance in staphylococci. Clin Infect Dis. 2005; 40:280-285.
13. Daurel C, Huet C, Dhalluin A, et al. Differences in potential for selection of clindamycin-resistant mutants between inducible erm(A) and erm(C) Staphylococcus aureus genes. J Clin Microbiol. 2008;46:546-550.
14. Leclercq R. Mechanisms of resistance to macro-lides and lincosamides. Clin Infect Dis. 2002;34: 482-492.
15. Weisblum B. Insights into erythromycin action. Antimicrob Agents Chemother. 1995;39:797-805.
16. Dubnau D. Translational attenuation: the regulation of bacterial resistance. CRC Crit Rev Bio-chem. 1984;16:103-132.
17. Vazquez-Laslop N, Thum C, Mankin A. Molecular mechanism of drug-dependent ribo-some stalling. Mol Cell. 2008;30:190-202.
18. Siberry GK, Tekle T, Carroll K, et al. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clin-damycin resistance in vitro. Clin Infect Dis. 2003; 37:1257-1260.
19. Steward CD, Raney P, Morrell A, et al. Testing for induction of clindamycin resistance in eryth-romycin-resistant isolates of Staphylococcus au-reus. J Clin Microbiol. 2005;43:1716-1721.
20. NCCLS (CLSI). Performance standards for antimicrobial susceptibility testing. NCCLS (CLSI). Wayne, PA, 2004. M100-S14.
21. Stevens DL, Ma Y, Salmi D, et al. Impact of antibiotics on expression of virulence-associated exotoxin genes. J Infect Dis. 2007;195: 202-211.
22. Stevens DL, Gibbons A, Bergstrom R, et al. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis. 1988;158: 23-28.
23. Zimbelman J, Palmer A, Todd J, et al. Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J. 1999;18:1096-1100